NEW YORK (GenomeWeb News) – MDxHealth said today that revenues in the third quarter rose 145 percent year over year, driven by a 141 percent increase in commercial revenues.

For the three months ended Sept. 30, MDxHealth's total revenues increased to €925,000 ($1.2 million) from €378,000 a year ago, as its commercial revenues climbed to €644,000 from €267,000.

The firm, based in Liege, Belgium, and with offices in Irvine, Calif., did not disclose its expenses for the third quarter. Its net loss for the period increased to €2.3 million from €1.9 million a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.